Last reviewed · How we verify
Polyethylene Glycols
Polyethylene Glycols is a Osmotic laxative Small molecule drug developed by Tomas Bata Hospital, Czech Republic. It is currently FDA-approved for Constipation, Bowel preparation for colonoscopy and other gastrointestinal procedures. Also known as: glycerin enema, asol, Miralax, Coolprep®; Taejoon Pharmaceuticals, Seoul, Korea.
Polyethylene glycols act as osmotic laxatives that draw water into the intestinal lumen to promote bowel movements.
Polyethylene glycols act as osmotic laxatives that draw water into the intestinal lumen to promote bowel movements. Used for Constipation, Bowel preparation for colonoscopy and other gastrointestinal procedures.
At a glance
| Generic name | Polyethylene Glycols |
|---|---|
| Also known as | glycerin enema, asol, Miralax, Coolprep®; Taejoon Pharmaceuticals, Seoul, Korea |
| Sponsor | Tomas Bata Hospital, Czech Republic |
| Drug class | Osmotic laxative |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Polyethylene glycols (PEGs) are inert polymers that are poorly absorbed in the gastrointestinal tract. They create an osmotic gradient that pulls water into the bowel lumen, increasing stool bulk and frequency without being metabolized or causing electrolyte imbalances. This mechanism makes them effective for treating constipation and for bowel preparation prior to colonoscopy.
Approved indications
- Constipation
- Bowel preparation for colonoscopy and other gastrointestinal procedures
Common side effects
- Nausea
- Abdominal bloating
- Abdominal cramping
- Vomiting
Key clinical trials
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis (PHASE3)
- A Study in Healthy Men to Find Out How BI 425809 is Taken up and Handled by the Body (PHASE1)
- The Efficacy and Palatability of Developed Polyethylene Glycol-based Formula for Children With Functional Constipation (NA)
- Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission (NA)
- Pre-operative Polyethylene Glycol 3350 for Minimally Invasive Urogynecologic Surgery (PHASE4)
- Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS) (PHASE4)
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Polyethylene Glycols CI brief — competitive landscape report
- Polyethylene Glycols updates RSS · CI watch RSS
- Tomas Bata Hospital, Czech Republic portfolio CI
Frequently asked questions about Polyethylene Glycols
What is Polyethylene Glycols?
How does Polyethylene Glycols work?
What is Polyethylene Glycols used for?
Who makes Polyethylene Glycols?
Is Polyethylene Glycols also known as anything else?
What drug class is Polyethylene Glycols in?
What development phase is Polyethylene Glycols in?
What are the side effects of Polyethylene Glycols?
Related
- Drug class: All Osmotic laxative drugs
- Manufacturer: Tomas Bata Hospital, Czech Republic — full pipeline
- Therapeutic area: All drugs in Gastroenterology
- Indication: Drugs for Constipation
- Indication: Drugs for Bowel preparation for colonoscopy and other gastrointestinal procedures
- Also known as: glycerin enema, asol, Miralax, Coolprep®; Taejoon Pharmaceuticals, Seoul, Korea
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing